Karien Esterhuizen1, J Zander Lindeque1, Shayne Mason1, Francois H van der Westhuizen1, Richard J Rodenburg2, Paul de Laat2, Jan A M Smeitink2, Mirian C H Janssen2,3, Roan Louw4,5. 1. Mitochondria Research Laboratory, Human Metabolomics, North-West University, Potchefstroom, South Africa. 2. Department of Pediatrics, Radboud Center for Mitochondrial Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 3. Department of Internal Medicine, Radboud Center for Mitochondrial Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 4. Mitochondria Research Laboratory, Human Metabolomics, North-West University, Potchefstroom, South Africa. Roan.Louw@nwu.ac.za. 5. Human Metabolomics, Faculty of Natural and Agricultural Sciences, North-West University, Potchefstroom Campus, Private Bag X6001, Potchefstroom, South Africa. Roan.Louw@nwu.ac.za.
Abstract
INTRODUCTION: The m.3243A > G mitochondrial DNA mutation is one of the most common mitochondrial disease-causing mutations, with a carrier rate as high as 1:400. This point mutation affects the MT-TL1 gene, ultimately affecting the oxidative phosphorylation system and the cell's energy production. Strikingly, the m.3243A > G mutation is associated with different phenotypes, including mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD) and myopathy. OBJECTIVES: We investigated urine metabolomes of MELAS, MIDD and myopathy patients in order to identify affected metabolic pathways and possible treatment options. METHODS: A multiplatform metabolomics approach was used to comprehensively analyze the metabolome and compare metabolic profiles of different phenotypes caused by the m.3243A > G mutation. Our analytical array consisted of NMR spectroscopy, LC-MS/MS and GC-TOF-MS. RESULTS: The investigation revealed phenotypic specific metabolic perturbations, as well as metabolic similarities between the different phenotypes. We show that glucose metabolism is highly disturbed in the MIDD phenotype, but not in MELAS or myopathy, remodeled fatty acid oxidation is characteristic of the MELAS patients, while one-carbon metabolism is strongly modified in both MELAS and MIDD, but not in the myopathy group. Lastly we identified increased creatine in the urine of the myopathy patients, but not in MELAS or MIDD. CONCLUSION: We conclude by giving novel insight on the phenotypes of the m.3243A > G mutation from a metabolomics point of view. Directives are also given for future investigations that could lead to better treatment options for patients suffering from this debilitating disease.
INTRODUCTION: The m.3243A > G mitochondrial DNA mutation is one of the most common mitochondrial disease-causing mutations, with a carrier rate as high as 1:400. This point mutation affects the MT-TL1 gene, ultimately affecting the oxidative phosphorylation system and the cell's energy production. Strikingly, the m.3243A > G mutation is associated with different phenotypes, including mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), maternally inherited diabetes and deafness (MIDD) and myopathy. OBJECTIVES: We investigated urine metabolomes of MELAS, MIDD and myopathypatients in order to identify affected metabolic pathways and possible treatment options. METHODS: A multiplatform metabolomics approach was used to comprehensively analyze the metabolome and compare metabolic profiles of different phenotypes caused by the m.3243A > G mutation. Our analytical array consisted of NMR spectroscopy, LC-MS/MS and GC-TOF-MS. RESULTS: The investigation revealed phenotypic specific metabolic perturbations, as well as metabolic similarities between the different phenotypes. We show that glucose metabolism is highly disturbed in the MIDD phenotype, but not in MELAS or myopathy, remodeled fatty acid oxidation is characteristic of the MELAS patients, while one-carbon metabolism is strongly modified in both MELAS and MIDD, but not in the myopathy group. Lastly we identified increased creatine in the urine of the myopathypatients, but not in MELAS or MIDD. CONCLUSION: We conclude by giving novel insight on the phenotypes of the m.3243A > G mutation from a metabolomics point of view. Directives are also given for future investigations that could lead to better treatment options for patients suffering from this debilitating disease.
Entities:
Keywords:
MELAS; MIDD; Metabolomics; Mitochondrial disease; Myopathy; m.3243A > G
Authors: Fabian Baertling; Richard J Rodenburg; Jörg Schaper; Jan A Smeitink; Werner J H Koopman; Ertan Mayatepek; Eva Morava; Felix Distelmaier Journal: J Neurol Neurosurg Psychiatry Date: 2013-06-14 Impact factor: 10.154
Authors: Randall M Chin; Xudong Fu; Melody Y Pai; Laurent Vergnes; Heejun Hwang; Gang Deng; Simon Diep; Brett Lomenick; Vijaykumar S Meli; Gabriela C Monsalve; Eileen Hu; Stephen A Whelan; Jennifer X Wang; Gwanghyun Jung; Gregory M Solis; Farbod Fazlollahi; Chitrada Kaweeteerawat; Austin Quach; Mahta Nili; Abby S Krall; Hilary A Godwin; Helena R Chang; Kym F Faull; Feng Guo; Meisheng Jiang; Sunia A Trauger; Alan Saghatelian; Daniel Braas; Heather R Christofk; Catherine F Clarke; Michael A Teitell; Michael Petrascheck; Karen Reue; Michael E Jung; Alison R Frand; Jing Huang Journal: Nature Date: 2014-05-14 Impact factor: 49.962
Authors: Karien Esterhuizen; J Zander Lindeque; Shayne Mason; Francois H van der Westhuizen; Anu Suomalainen; Anna H Hakonen; Christopher J Carroll; Richard J Rodenburg; Paul B de Laat; Mirian C H Janssen; Jan A M Smeitink; Roan Louw Journal: Mitochondrion Date: 2018-02-19 Impact factor: 4.160
Authors: Xiaoyan Robert Bao; Shao-En Ong; Olga Goldberger; Jun Peng; Rohit Sharma; Dawn A Thompson; Scott B Vafai; Andrew G Cox; Eizo Marutani; Fumito Ichinose; Wolfram Goessling; Aviv Regev; Steven A Carr; Clary B Clish; Vamsi K Mootha Journal: Elife Date: 2016-06-16 Impact factor: 8.140
Authors: Jana Buzkova; Joni Nikkanen; Sofia Ahola; Anna H Hakonen; Ksenia Sevastianova; Topi Hovinen; Hannele Yki-Järvinen; Kirsi H Pietiläinen; Tuula Lönnqvist; Vidya Velagapudi; Christopher J Carroll; Anu Suomalainen Journal: EMBO Mol Med Date: 2018-12 Impact factor: 12.137
Authors: Mélissa Carbonneau; Laurence M Gagné; Marie-Eve Lalonde; Marie-Anne Germain; Alena Motorina; Marie-Christine Guiot; Blandine Secco; Emma E Vincent; Anthony Tumber; Laura Hulea; Jonathan Bergeman; Udo Oppermann; Russell G Jones; Mathieu Laplante; Ivan Topisirovic; Kevin Petrecca; Marc-Étienne Huot; Frédérick A Mallette Journal: Nat Commun Date: 2016-09-14 Impact factor: 17.694